2
|
Sun J, Cao Q, Lin S, Chen Y, Liu X, Hong Q. Knockdown of CALM2 increases the sensitivity to afatinib in HER2-amplified gastric cancer cells by regulating the Akt/FoxO3a/Puma axis. Toxicol In Vitro 2023; 87:105531. [PMID: 36460225 DOI: 10.1016/j.tiv.2022.105531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Revised: 11/28/2022] [Accepted: 11/28/2022] [Indexed: 12/03/2022]
Abstract
Gastric cancer (GC) is a global health issue that lacks effective treatment options. Afatinib is a tyrosine kinase inhibitor (TKI) that has shown promising results in the treatment of GC. However, resistance to afatinib is inevitable and hampers its clinical application. To date, there is limited knowledge regarding the mechanisms underlying the resistance of GC cells to afatinib. This study aimed to identify novel factors that may contribute to the resistance of GC cells to afatinib. We found that upregulation of calmodulin 2 (CALM2), a member of the CALM family, confers resistance to afatinib in GC cells. Knockdown of CALM2 can overcome the resistance to afatinib by promoting mitochondrial apoptosis in a caspase-dependent manner. Mechanistically, it was found that the downregulation of CALM2 led to the upregulation of the FoxO3a/Puma axis. Inhibition of either FoxO3a or Puma abrogated the effects of CALM2 downregulation in GC cells. In addition, we revealed that CALM2 knockdown inhibited Akt signaling, which is responsible for blocking the FoxO3a/Puma axis. Altogether, our results indicated that CALM2 could be considered a potential target to overcome the resistance of GC cells to afatinib.
Collapse
Affiliation(s)
- Jianli Sun
- Department of gastroenterology, Zhenhai People's Hospital, Ningbo, Zhejiang Province, China
| | - Qunfen Cao
- Department of gastroenterology, Zhenhai People's Hospital, Ningbo, Zhejiang Province, China
| | - Saizheng Lin
- Department of gastroenterology, Zhenhai People's Hospital, Ningbo, Zhejiang Province, China
| | - Yonghua Chen
- Department of gastroenterology, Zhenhai People's Hospital, Ningbo, Zhejiang Province, China
| | - Xiao Liu
- Department of gastroenterology, Zhenhai People's Hospital, Ningbo, Zhejiang Province, China
| | - Qiongyi Hong
- Department of gastroenterology, Zhenhai People's Hospital, Ningbo, Zhejiang Province, China.
| |
Collapse
|
3
|
Yang X, Ren H, Xu Y, Peng X, Yu W, Shen Z. Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases. Eur J Med Res 2023; 28:27. [PMID: 36642742 PMCID: PMC9841677 DOI: 10.1186/s40001-022-00894-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Accepted: 11/09/2022] [Indexed: 01/17/2023] Open
Abstract
Radiotherapy and targeted therapy are essential treatments for patients with brain metastases from human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, the combination of radiotherapy and targeted therapy still needs to be investigated, and neurotoxicity induced by radiotherapy for brain metastases has also become an important issue of clinical concern. It remained unclear how to achieve the balance of efficacy and toxicity with the application of new radiotherapy techniques and new targeted therapy drugs. This article reviews the benefits and potential risk of combining radiotherapy and targeted therapy for HER2-positive breast cancer with brain metastases.
Collapse
Affiliation(s)
- Xiaojing Yang
- grid.16821.3c0000 0004 0368 8293Department of Oncology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600, Yishan Road, Shanghai, 200233 China ,grid.16821.3c0000 0004 0368 8293Department of Radiation Oncology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Hanru Ren
- grid.8547.e0000 0001 0125 2443Department of Orthopedics, Pudong Medical Center, Shanghai Pudong Hospital, Fudan University, Shanghai, China
| | - Yi Xu
- grid.16821.3c0000 0004 0368 8293Department of Oncology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600, Yishan Road, Shanghai, 200233 China
| | - Xue Peng
- grid.16821.3c0000 0004 0368 8293Department of Breast Surgery, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Wenxi Yu
- grid.16821.3c0000 0004 0368 8293Department of Oncology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600, Yishan Road, Shanghai, 200233 China
| | - Zan Shen
- grid.16821.3c0000 0004 0368 8293Department of Oncology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600, Yishan Road, Shanghai, 200233 China
| |
Collapse
|
4
|
Gao W, Yuan Z, Zhao X, Wang S, Lai S, Ni K, Zhan Y, Liu Z, Liu L, Xin R, Yin X, Zhou X, Liu X, Zhang X, Zhang Q, Li G, Wang W, Zhang C. The prognostic and clinical value of p53 upregulated modulator of apoptosis expression in solid tumours: a meta-analysis and TCGA data review. Expert Rev Mol Diagn 2022; 22:811-819. [DOI: 10.1080/14737159.2022.2125802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- Weifeng Gao
- Department of Colorectal Surgery, Tianjin Union Medical Center, 300121 Tianjin, China
- Tianjin Institute of Coloproctology, 300121 Tianjin, China
- The Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, Tianjin, China
| | - Zhen Yuan
- School of Medicine, Nankai University, 300071 Tianjin, China
| | - Xuanzhu Zhao
- Department of Colorectal Surgery, Tianjin Union Medical Center, 300121 Tianjin, China
- School of integrative medicine, Tianjin University of Traditional Chinese Medicine, 301617 Tianjin, China
| | - Shuyuan Wang
- School of Medicine, Nankai University, 300071 Tianjin, China
| | - Sizhen Lai
- Department of Colorectal Surgery, Tianjin Union Medical Center, 300121 Tianjin, China
- School of integrative medicine, Tianjin University of Traditional Chinese Medicine, 301617 Tianjin, China
| | - Kemin Ni
- Department of Colorectal Surgery, Tianjin Union Medical Center, 300121 Tianjin, China
- School of Medicine, Nankai University, 300071 Tianjin, China
| | - Yixiang Zhan
- Department of Colorectal Surgery, Tianjin Union Medical Center, 300121 Tianjin, China
- Tianjin Institute of Coloproctology, 300121 Tianjin, China
| | - Zhaoce Liu
- Department of Colorectal Surgery, Tianjin Union Medical Center, 300121 Tianjin, China
- School of Medicine, Nankai University, 300071 Tianjin, China
| | - Lina Liu
- Department of Colorectal Surgery, Tianjin Union Medical Center, 300121 Tianjin, China
| | - Ran Xin
- School of Medicine, Nankai University, 300071 Tianjin, China
| | - Xin Yin
- School of Medicine, Nankai University, 300071 Tianjin, China
| | - Xingyu Zhou
- School of Medicine, Nankai University, 300071 Tianjin, China
| | - Xinyu Liu
- Department of Colorectal Surgery, Tianjin Union Medical Center, 300121 Tianjin, China
- Tianjin Medical University, 300041 Tianjin, China
| | - Xipeng Zhang
- Department of Colorectal Surgery, Tianjin Union Medical Center, 300121 Tianjin, China
- Tianjin Institute of Coloproctology, 300121 Tianjin, China
- The Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, Tianjin, China
| | - Qinghuai Zhang
- Department of Colorectal Surgery, Tianjin Union Medical Center, 300121 Tianjin, China
- Tianjin Institute of Coloproctology, 300121 Tianjin, China
- The Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, Tianjin, China
| | - Guoxun Li
- Department of Colorectal Surgery, Tianjin Union Medical Center, 300121 Tianjin, China
- Tianjin Institute of Coloproctology, 300121 Tianjin, China
- The Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, Tianjin, China
| | - Wenhong Wang
- Department of Colorectal Surgery, Tianjin Union Medical Center, 300121 Tianjin, China
- Tianjin Institute of Coloproctology, 300121 Tianjin, China
- The Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, Tianjin, China
| | - Chunze Zhang
- Department of Colorectal Surgery, Tianjin Union Medical Center, 300121 Tianjin, China
- Tianjin Institute of Coloproctology, 300121 Tianjin, China
- The Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, Tianjin, China
| |
Collapse
|
6
|
Lou J, Lv JX, Zhang YP, Liu ZJ. OSI-027 inhibits the tumorigenesis of colon cancer through mediation of c-Myc/FOXO3a/PUMA axis. Cell Biol Int 2022; 46:1204-1214. [PMID: 35293663 DOI: 10.1002/cbin.11792] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2021] [Revised: 01/16/2022] [Accepted: 03/13/2022] [Indexed: 11/07/2022]
Abstract
Colon cancer is a gastrointestinal malignancy which is one of the leading causes of tumor-associated deaths. It has been reported that mTOR can lead to the progression of colon cancer. However, the mechanism by which mTOR inhibitor (OSI-027) mediates the tumorigenesis of colon cancer remains largely unknown. Cell function of colon cancer was investigated by CCK-8 flow cytometry and TUNEL staining. In addition, qRT-PCR and western blot were used to investigate the mechanism underlying the function of OSI-027 in colon cancer. OSI-027 dose-dependently reduced colon cancer cell viability through inducing the cell apoptosis. In addition, OSI-027 induced the apoptosis of colon cancer cells via upregulation of PUMA. OSI-027 promoted the expression of PUMA by activation of FOXO3a, and c-Myc knockdown partially increased FOXO3a and PUMA level. Moreover, OSI-027 attenuated the tumor growth of colon cancer through mediation of mTOR/c-Myc/FOXO3a axis. OSI-027 attenuates colon cancer progression through mediation of c-Myc/FOXO3a/PUMA axis. Thereby, this research might shed new insights on exploring the strategies against colon cancer. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Jie Lou
- Department of Gastroenterology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.,Department of Gastroenterology, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, 315000, Zhejiang Province, China
| | - Jian-Xin Lv
- Department of Gastroenterology, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, 315000, Zhejiang Province, China
| | - You-Ping Zhang
- Department of Gastroenterology, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, 315000, Zhejiang Province, China
| | - Zhan-Ju Liu
- Department of Gastroenterology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China
| |
Collapse
|
7
|
Isoforms of the p53 Family and Gastric Cancer: A Ménage à Trois for an Unfinished Affair. Cancers (Basel) 2021; 13:cancers13040916. [PMID: 33671606 PMCID: PMC7926742 DOI: 10.3390/cancers13040916] [Citation(s) in RCA: 29] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2020] [Revised: 02/06/2021] [Accepted: 02/17/2021] [Indexed: 12/17/2022] Open
Abstract
Simple Summary The p53 family is a complex family of transcription factors with different cellular functions that are involved in several physiological processes. A massive amount of data has been accumulated on their critical role in the tumorigenesis and the aggressiveness of cancers of different origins. If common features are observed, there are numerous specificities that may reflect particularities of the tissues from which the cancers originated. In this regard, gastric cancer tumorigenesis is rather remarkable, as it is induced by bacterial and viral infections, various chemical carcinogens, and familial genetic alterations, which provide an example of the variety of molecular mechanisms responsible for cell transformation and how they impact the p53 family. This review summarizes the knowledge gathered from over 40 years of research on the role of the p53 family in gastric cancer, which still displays one of the most elevated mortality rates amongst all types of cancers. Abstract Gastric cancer is one of the most aggressive cancers, with a median survival of 12 months. This illustrates its complexity and the lack of therapeutic options, such as personalized therapy, because predictive markers do not exist. Thus, gastric cancer remains mostly treated with cytotoxic chemotherapies. In addition, less than 20% of patients respond to immunotherapy. TP53 mutations are particularly frequent in gastric cancer (±50% and up to 70% in metastatic) and are considered an early event in the tumorigenic process. Alterations in the expression of other members of the p53 family, i.e., p63 and p73, have also been described. In this context, the role of the members of the p53 family and their isoforms have been investigated over the years, resulting in conflicting data. For instance, whether mutations of TP53 or the dysregulation of its homologs may represent biomarkers for aggressivity or response to therapy still remains a matter of debate. This uncertainty illustrates the lack of information on the molecular pathways involving the p53 family in gastric cancer. In this review, we summarize and discuss the most relevant molecular and clinical data on the role of the p53 family in gastric cancer and enumerate potential therapeutic innovative strategies.
Collapse
|